payable618,258752,742Accrued liabilities735,386732,296Accrued interest payable28,5944,693Derivative instruments—1,230Current operating lease liabilities14,65637,629Other current liabilities11,89886,637Total current liabilities1,450,5871,683,978Long-term debt1,479,581842,600Deferred tax liabilities1,615,8501,496,442Asset retirement obligations432,802282,369Derivative instruments—1,016Operating lease liabilities10,51815,190Other liabilities4,9828,150Total liabilities4,994,3204,329,745Commitments and contingen ...

– Total Revenues increased 33.0% for the quarter over the prior year period to $68.8 million – – Organic Revenue Growth Rate* of 11.7% for the quarter – – Net income of $14.4 million for the quarter – – Adjusted EBITDA* increased 56.9% for the quarter over the prior year period to $21.7 million - – Share Repurchase Authorization approved for up to $50 million - THE WOODLANDS, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- TWFG, Inc. (“TWFG”, the “Company” or “we”) (NASDAQ: TWFG), a high-growth insurance distribut ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. “In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Offic ...

LOUISVILLE, Ky., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company", "CDI", "we") today reported business results for the quarter and full year ended December 31, 2025. Company Highlights Fourth quarter 2025 financial results, as compared to the prior year quarter: Record net revenue $665.9 million, up $41.7 million or 7%Net income attributable to CDI of $51.3 million, down $20.4 million or 28%Record Adjusted EBITDA of $247.0 million, up $10.4 million or 4% On Septe ...

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, I ...

BALTIMORE, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sinclair, Inc. (Nasdaq: SBGI), the "Company" or "Sinclair," today reported financial results for the three and twelve months ended December 31, 2025. Highlights: Met or exceeded guidance on all key financial metricsFull year Adjusted EBITDA of $483 millionFull-year core advertising revenue grew by $71 million over 2024 CEO Comment: “Sinclair delivered a strong fourth quarter, with total revenue exceeding the midpoint of guidance and Adjusted EBITDA above expectat ...

BlueLinx Q4 and Full Year 2025 Results Delivering What Matters February 25, 2026 © BlueLinx 2026. All Rights Reserved. 1 Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements include, without limitation, any statement that predicts, forecasts, indicates or implies future results, performance, liquidity levels or achievements, and may contain the words "believe," "anticipate," "could", "expect," "estimate," "intend," "may", "project," "plan," "should", "will" ...

Core Insights - Precipio, Inc. has reported strong preliminary financial results for Q4-2025 and fiscal year 2025, highlighting significant growth in revenue and positive cash flow metrics [1][5]. Financial Performance - Revenue Growth: Precipio's revenues increased from $18.5 million in 2024 to $24.0 million in 2025, representing a 30% year-over-year increase. Q4-2025 revenues were $6.7 million, up 23% from $5.4 million in Q4-2024 [5]. - Positive Adjusted EBITDA: The company will report Adjusted EBITDA of $0.95 million for Q4-2025 and $1.23 million for the full year 2025, compared to $0.40 million in Q4-2024 and a loss of $1.5 million for the full year 2024 [5]. - Positive Operating Cash Flow: Precipio will report $368,000 of positive operating cash flow during Q4-2025 and a total of $688,000 for 2025, compared to $439,000 generated from operations in 2024 [5]. Management Commentary - The CEO, Ilan Danieli, emphasized the importance of becoming an EBITDA and cash-flow positive business, allowing for investments in long-term growth projects rather than focusing solely on short-term cash burn [2]. The company experienced a strong performance in 2025, with shareholders seeing their value triple [2]. Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and improve patient outcomes [6].

Solaris Energy Infrastructure, Inc. Q4 and Full Year 2025 Earnings Supplement February 24, 2026 Solaris Energy Infrastructure Solaris Energy Infrastructure Recent Updates and Q4 2025 Highlights Strong Q4 2025 Results Reported Q4 2025 performance with Adjusted EBITDA (1) of approximately $69 million New Guidance Raised Q1 2026 guidance for Adjusted EBITDA (2) slightly to $72-77 million from $70-75 million previously; Established Q2 2026 Adjusted EBITDA (2) guidance of $76-84 million Strengthened Balance Shee ...

Corporate Information & Analyst Coverage | Key Management | | | --- | --- | | Andrew Spodek | Chief Executive Officer | | Jeremy Garber | President, Treasurer & Secretary | | Steve Bakke | Chief Financial Officer | | Board of Directors | Board Responsibilities | | Patrick Donahoe | Chair of the Board, Member - Audit Committee | | Andrew Spodek | Chief Executive Officer, Director | | Barry Lefkowitz | Chair of Audit Committee, Member - Corporate Governance & Compensation Committee | | Anton Feingold | Chair ...